Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIOGEN | 3 | 54 | -0,33 % | ||
| ALUMIS | 3 | 2 | -5,62 % | ||
| ARCUTIS BIOTHERAPEUTICS | 3 | - | -5,23 % | ||
| BIONTECH | 2 | 13 | -1,84 % | ||
| INCYTE | 1 | 25 | -1,23 % | ||
| KYMERA THERAPEUTICS | 1 | 6 | -2,42 % | ||
| PROTAGONIST THERAPEUTICS | 1 | 3 | +2,81 % | ||
| ROIVANT SCIENCES | 1 | 3 | +1,40 % | ||
| AMGEN | - | 27 | -0,11 % | ||
| REGENERON PHARMACEUTICALS | - | 22 | -0,12 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:30 | BioNTech: Wichtiger Termin am Montag - Was das für Ihr Depot bedeutet | Hebelschein-Spekulant | |||
| 09:50 | Sonntag-Meldung zu BIONTECH SE ADR: Jetzt wird's ernst! | 6 | Maximilian Berger | ||
| Sa | Biogen meldet positive Phase-2-Daten für Haut-Lupus-Wirkstoff | 3 | Investing.com Deutsch | ||
| Sa | Biogen Inc.: Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity | 550 | GlobeNewswire (Europe) | In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear... ► Artikel lesen | |
| Sa | Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting | 555 | Business Wire |
Phase 3 data from the STOP-HS program demonstrate povorcitinib's substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS).
... ► Artikel lesen | |
| Sa | Biogen reports positive Phase 2 results for lupus skin drug | 4 | Investing.com | ||
| Sa | Roivant Sciences: New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis | 1 | GlobeNewswire (USA) | ||
| Sa | Alumis reports Phase 3 psoriasis trial results for envudeucitinib | 1 | Investing.com | ||
| Sa | Alumis meldet überzeugende Phase-3-Ergebnisse für Psoriasis-Wirkstoff Envudeucitinib | 2 | Investing.com Deutsch | ||
| Sa | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | 1 | GlobeNewswire (USA) | ||
| Sa | Sanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis | 419 | AFX News | PARIS (dpa-AFX) - Sanofi SA (SNY, SNYNF,SAN.PA) announced encouraging results from three Phase 3 clinical trials-COAST 1, COAST 2, and SHORE-evaluating amlitelimab, a fully human non-T cell... ► Artikel lesen | |
| Sa | Sanofi meldet positive Phase-3-Daten für Medikament gegen atopische Dermatitis | 8 | Investing.com Deutsch | ||
| Sa | Arcutis: Studiendaten belegen Wirksamkeit von Roflumilast-Creme bei Säuglingen mit Neurodermitis | 4 | Investing.com Deutsch | ||
| Sa | Sanofi reports positive phase 3 data for atopic dermatitis drug | 6 | Investing.com | ||
| Sa | Arcutis presents trial data on roflumilast cream for infants | 2 | Investing.com | ||
| Sa | Sanofi: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session | 1.446 | GlobeNewswire (Europe) | AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed... ► Artikel lesen | |
| Sa | Kymera Therapeutics, Inc.: Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| Sa | Arcutis Biotherapeutics, Inc.: Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting | 3 | GlobeNewswire (USA) | ||
| Sa | Protagonist Therapeutics: Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology Annual Meeting | 958 | ACCESS Newswire | One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults further... ► Artikel lesen | |
| Sa | BioCryst strebt Milliardenumsatz an und stärkt HAE-Portfolio mit Navenibart | 6 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.